logo
Less FVC Decline in Progressive PF With Oral Nerandomilast

Less FVC Decline in Progressive PF With Oral Nerandomilast

Medscape20-05-2025
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), results of the phase 3 randomized FIBRONEER-ILD trial showed.
Among 1176 patients, the mean decline from baseline in FVC at 1 year was significantly greater for those assigned to receive a placebo than those assigned to receive nerandomilast at either of two doses, reported Marlies S. Wijsenbeek, MD, PhD, from Erasmus Medical Center in Rotterdam, the Netherlands.
'I think, personally, that these results are really a major step forward. After a decade of failed phase 3, we have now a positive trial which is really important for treatment of people with IPF [idiopathic PF],' she said in oral abstract session at American Thoracic Society (ATS) 2025 International Conference.
The study was also published online in The New England Journal of Medicine to coincide with the presentation.
Phosphodiesterase 4B (PDE-4B) Inhibitor
Nerandomilast is an oral preferential inhibitor of PDE-4B that has shown both antifibrotic and immunomodulatory effects in preclinical models.
In a phase 3 follow-on trial of this agent in patients with IPF (FIBRONEER-IPF), nerandomilast was associated with a smaller decline in FVC compared with placebo over 1 year.
In FIBRONEER-ILD, which was conducted at 403 sites in 44 countries, patients with fibrosing interstitial lung disease (ILD) other than IPF were enrolled. After stratification by prior nintedanib (OFEV) use and high-resolution CT pattern (either usual interstitial pneumonia [UIP] or UIP-like fibrotic pattern vs other fibrotic patterns), patients were randomized in a 1:1:1 ratio to receive either nerandomilast twice daily at doses of 18 or 9 mg or placebo. Approximately 44% of patients in each study arm were on nintedanib background therapy.
The adjusted mean change in FVC at week 52, the primary endpoint, was −98.6 mL for patients assigned to nerandomilast 18 mg, −84.6 mL for those assigned to nerandomilast 9 mg, and −165.8 mL for those assigned to placebo.
The adjusted difference between 9-mg nerandomilast and placebo groups was 81.1 mL ( P < .001), and the adjusted difference between 18-mg and placebo groups was 67.2 mL ( P < .001).
The effect of nerandomilast was generally consistent across ILD subtypes, Wijsenbeek said.
At the time of data cutoff, a first acute exacerbation of ILD, hospitalization for a respiratory cause, or death — a key composite secondary endpoint — occurred in 95 patients on the 18-mg dose, 110 on the 9-mg dose, and 122 patients on placebo. These differences did not reach statistical significance, however.
A total of 24 patients in the 18-mg group (6.1%), 33 in the 9-mg group (8.4%), and 50 in the placebo group (12.8%) died during the study. The hazard ratio for death among patients in the 18-mg vs placebo group was 0.48 (95% CI, 0.30-0.79), and the hazard ratio for the 9-mg vs placebo group was 0.60 (95% CI, 0.38-0.95).
Diarrhea, the most common adverse event, was reported in 36.6% of patients taking 18 mg nerandomilast twice daily, 29.5% of those taking 9 mg twice daily, and 24.7% of those on placebo. Diarrhea leading to discontinuation was also higher in both the nerandomilast dosing groups than in the placebo group.
In the question and answer following her talk, Gisli Jenkins, MD, PhD, from Imperial College London, London, England, asked Wijsenbeek whether slowing absolute decline in FVC was the best endpoint for the trial.
'I think there is a lot of debate [about] what is the best endpoint. I think it's the best endpoint we currently have,' she replied.
Ganesh Raghu, MD, from the University of Washington in Seattle, commented that FIBRONEER-ILD efficacy data were similar to those seen a decade ago with nintedanib and asked Wijsenbeek whether she could put the new data in context with existing therapies.
She replied that although the efficacy of the agents are similar, patients appear to tolerate nerandomilast better than nintedanib, 'so that's a gain, in my opinion.'
She added that any additional clinical benefit, even if it's only incremental, is better for patients, and she noted that although the study was not powered to detect a decrease in acute exacerbations, hospitalizations, or deaths, the data pointed to a benefit for nerandomilast.
In an editorial accompanying the study in NEJM , Joyce S. Lee, MD, from the University of Colorado Anschutz Medical Campus in Aurora, Colorado, commented that the FIBRONEER-IPF and FIBRONEER-ILD trials 'represent a meaningful advancement in the treatment landscape for persons living with IPF and progressive ILD other than IPF. Important issues that our community of clinicians will need to address moving forward nonetheless remain — decisions regarding the choice of first-line therapy, indications for up-front combination therapy as compared with add-on therapy, and the role of immunosuppression in patients with non-IPF ILD and a PPF phenotype.'
The study was supported by Boehringer Ingelheim.
Wijsenbeek reported serving on a scientific advisory board and receiving speaker fees and unrestricted grants, all paid to her institution and not her personally. Lee and Jenkins reported having financial relationships with Boehringer Ingelheim and others. Raghu disclosed advisory board/consulting activities for various companies, not including Boehringer Ingelheim.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump administration recommends location verification for AI chips
Trump administration recommends location verification for AI chips

Yahoo

time12 minutes ago

  • Yahoo

Trump administration recommends location verification for AI chips

By Stephen Nellis SAN FRANCISCO (Reuters) -U.S. President Donald Trump's administration on Wednesday recommended implementing export controls that would verify the location of advanced artificial intelligence chips, a move that was applauded by U.S. lawmakers from both parties in both houses of Congress. The recommendation was part of a broader AI blueprint released on Wednesday that aimed to boost exports of AI hardware and software to U.S. allies and relax U.S. environmental rules to speed the construction of new AI data centers. But the plan released Wednesday also said the U.S. should continue denying access to advanced U.S. AI chips made by companies like Nvidia and AMD to foreign adversaries. It added the U.S. government should "explore leveraging new and existing location verification features on advanced AI compute to ensure that the chips are not in countries of concern." The recommendation drew support from two lawmakers who previously introduced bills that would require location verification of chips after sale over concerns that they are finding their way to countries such as China, where their export is banned. Key details - such as how the technology would be implemented and how much cost it would add - remain to be worked out, both in the proposed bills and the Trump administration's recommendations. "I was encouraged to see that the recommended export control policy includes location verification mechanisms and aligns closely with our bipartisan Chip Security Act. I look forward to learning more of the technical details and next steps for end-use verification," Representative Bill Foster, an Illinois Democrat who helped introduce a chip-location bill in May, told Reuters. "Senator Cotton was pleased to see verification included in President Trump's AI Action Plan, as it's a vital part of his bipartisan, bicameral Chip Security Act and an important tool to keep advanced American technology out of the hands of Communist China," said Patrick McCann, a spokesperson for Senator Tom Cotton, an Arkansas Republican who introduced a similar bill in the U.S. Senate. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How Much Fat Can People with Diabetes Have Each Day?
How Much Fat Can People with Diabetes Have Each Day?

Health Line

time17 minutes ago

  • Health Line

How Much Fat Can People with Diabetes Have Each Day?

If you have diabetes, healthy fats are still an important part of your diet. However, eating too much saturated fat can lead to serious cardiovascular issues. For people with diabetes, monitoring carbohydrates often takes center stage when managing their diets. But that doesn't mean that other macronutrients should be ignored, especially when it comes to how much and what kind of fat someone with diabetes eats. Diets containing a lot of saturated fat are associated with a higher risk of heart disease and stroke, which are common comorbidities for diabetes. Understanding the different kinds of fats in foods and their effects on blood sugars is an important part of diabetes management. Let's take a closer look at dietary fats and their role in managing diabetes. Does fat raise blood sugar levels? Fat doesn't break down into glucose when it's digested. That means it doesn't directly cause blood glucose levels to rise. In fact, eating a balanced meal or snack that includes some fat can lead to more stable glucose levels. Fat, along with protein and fiber, slows digestion which also slows down the absorption of carbohydrates and smooths out the glucose spikes they can cause. But again, it's important to pay attention to the amount and type of fat to keep the meal or snack heart-healthy. How much fat should a person with diabetes have per day? Current dietary guidelines in the 2020-2025 Dietary Guidelines for Americans have moved away from recommending strict limits and amounts on the macronutrients and food groups people should eat. New guidelines embrace a more inclusive approach that recognizes and supports the need for personalized and culturally inclusive recommendations. Daily guidelines for dietary fat In the new guidelines with varying daily calorie limits, no specific number of daily grams of fat is recommended. The current guideline for adults is to limit overall daily fat intake to 20% to 35% of total daily calories and limit saturated fat to fewer than 10% of daily calorie intake. Translating that into the number of grams takes a little bit of math: Each gram of fat translates into 9 calories. Take the total number of calories for the day and divide that by 10 to get the number of calories from saturated fat. Then take that amount and divide that by 9 to get the top limit of daily grams of saturated fat. For example, for someone who eats 2,000 calories per day, that would mean eating 45 to 78 total grams of fat per day. Of this total, only 22 grams should be saturated fat. You can read more about the different kinds of fats, as detailed by the American Diabetes Association. While the new guidelines call for 'meeting food group needs with nutrient-dense foods and beverages, and staying within calorie limits,' calorie and nutritional limits are defined by a combination of age, sex, daily activity level (sedentary, moderately active, and active), and whether the person is pregnant or lactating. For example: for males who are 40 years or older, the daily calorie limit is about 2,200 calories depending on level of activity for females 40 years or older, the daily calorie limit could be roughly 1,800 calories per day for people who are pregnant, the daily limit could be as much as 452 additional calories than what's listed above, depending on the trimester Why include fats in our diets? Even though too much fat can lead to health issues, it cannot be eliminated from our diets completely. Fat makes it possible for the body to absorb fat-soluble vitamins A, D, E, and K. They also support cell function, give the body energy, and provide the body with fatty acids that it cannot make itself. That being said, it's important to limit the amount and kinds of fat eaten to support good health. Why is fat content on nutritional facts labels important for people with diabetes? Nutrition Facts labels are found on packaged foods and beverages and restaurant menus. These are helpful tools for understanding the kind and amount of fat we eat. These labels provide information about the calories, fat, carbohydrates, and key nutrients in each standard serving. On the label, the total number of grams of fat in a single serving of the food or beverage is listed. Underneath that, the amount of saturated fat and trans fat are listed separately as grams. This detail tells us not only how much fat is present, but also how much of that fat comes from less healthy sources. What are the different types of fat in foods? Fats are categorized into four groups: polyunsaturated monounsaturated saturated trans You may have heard of 'good' fats and 'bad' fats. Unsaturated fats are often labeled as 'good' fats. Saturated and trans fats are often labeled as 'bad' fats. To eat a balanced diet, it's best to lean into eating and cooking with unsaturated fats more often than other fats. Unsaturated fats (poly- and mono-) These fats offer some heart protection by maintaining blood levels of HDL (good) cholesterol and lowering levels of LDL (bad) cholesterol. Unsaturated fats are found in plant and fish oil and some nuts, including: olive oil corn oil canola oil sunflower oil oily fish including salmon, sardines, and trout avocados almonds, peanuts, and Brazil nuts pumpkin, flax, and sesame seeds Saturated fats Saturated fats are considered less healthy. Too much saturated fat can raise LDL and increase the risk of heart disease and stroke. Saturated fats are found in animal foods and some plant-based foods, including: coconut coconut oil palm oil palm kernel oil sausage, bacon, ground beef beef and pork milk, butter, dairy products (full fat and reduced fat) In the United States, the biggest dietary source of saturated fat comes from sandwiches, including burgers, tacos, and burritos — generally foods and dishes containing high fat meats and full fat dairy. Saturated fats are also found in desserts and sweet snacks. There is debate about whether saturated fat should be avoided. The ADA recommends limiting this type of fat, while the accredited Joslin Diabetes Center does not. All sources do agree that processed meats and highly processed foods and trans fats should be limited. Trans fats These fats can negatively affect heart health and circulation. They raise LDL and lower HDL cholesterol and contribute to inflammation and insulin resistance. Trans fats are most commonly manufactured by adding hydrogen to vegetable oil. This changes the liquid oil into solid fat at room temperature. Vegetable shortening and margarine used to be commonly made using trans fats. Trans fats can also be naturally present in some animal products from ruminant animals. These include dairy milk, butter, cheese, and some meats. In response to the negative effects trans fats have on heart health, the Food and Drug Administration (FDA) took action to ban trans fats known as partially hydrogenated oils. Naturally occurring trans fats do not promote inflammation like manufactured trans fats, which the FDA has banned since 2020.

Nutex Health Responds to Short Seller Report
Nutex Health Responds to Short Seller Report

Yahoo

time38 minutes ago

  • Yahoo

Nutex Health Responds to Short Seller Report

HOUSTON, July 23, 2025 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks, today provided the following response to a misleading short attack. The Company is aware of the allegations made in a recent short seller report that attempts to call into question the Company's collection process. As previously disclosed, Nutex Health has developed a robust internal process to code, bill and, if necessary after a federally mandated negotiation period, submit eligible medical claims to independent dispute resolution. The Company strongly disagrees with the allegations in the report and believes it is without merit. Further, the Company believes the report contains misrepresentations and conveys a misunderstanding of Nutex Health's business. Nutex Health expects to provide related updates in its upcoming earnings release and Form 10-Q for the second quarter of 2025 due on or before August 14, 2025. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Forward-Looking Statements Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, under the heading "Risk Factors" in Part II, Item IA thereof, and the risk factors and other cautionary statements contained in our other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. View original content: SOURCE Nutex Health, Inc. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store